Kornimate/medical-research-clean huggingface dataset:
the cease study: computer based educational module for the reduction of arthralgia syndrome associated with endocrine therapy for breast cancer

Conditions: Breast Cancer; Arthralgia

Summary: patients have been asked to participate in the cease study because their treating oncologist has recommended that they start an aromatase inhibitor medication. these medications are associated with joint complaints. the purpose of this study is to see whether a computer-based educational module is a feasible intervention to help address these symptoms. if the patients agree to participate, a research coordinator will test their grip strength and give them a computer log-on code. they will be shown how to log-on to complete the educational module and a few simple questionnaires. patients have the option to do this from home if they wish. in 3 months time, the investigators will ask patients to return to the clinic and have another grip strength evaluation and complete some additional questionnaires. the computer module and the follow up visit will each take about 30 minutes of time.


Eligibility criteria:
inclusion criteria: * post-menopausal stage i-iii breast cancer patients * starting or about to start aromatase inhibitor * english speaking with ability to read, write and use a computer to watch and listen to an educational module. * able to give informed consent exclusion criteria: * aromatase inhibitor (ai) use for more than 6 months * metastatic breast cancer * non-english speaking, or unable to read, write or use a computer to watch and listen to an educational module. * unable to give informed consent

Keywords: aromatase inhibitor arthralgia syndrome exercise
multispectral imaging to characterize patterns of vascular supply within lymphoepithelial mucosa in oropharyngeal cancer

Conditions: Oropharyngeal Carcinoma; Oropharynx Cancer

Summary: the purpose of this study is to characterize the blood supply at the base of the tongue and within the tonsil region. we hypothesize that high-resolution narrow band imaging (nbi) will improve the diagnosis of oropharyngeal carcinoma (opc). the goal is to provide the better assessment of tumor and thus providing better preoperative expectations to patients with opc or tumor extent prior to radiation therapy.


Eligibility criteria:
inclusion criteria: * age 18 years or older * written informed consent * patients with oropharyngeal carcinoma exclusion criteria: * tumors of the oral cavity or nasopharynx

Keywords: narrow band imaging oropharyngeal carcinoma
safety and efficacy study of autologous cultured adipose -derived stem cells for the crohn's fistula

Conditions: Crohn's Fistula

Summary: up to date, a sure cure for crohn's fistula does not known and the fistula recurrence rate is high. on 15 october 2008, orphan designation was granted by korea fda for human adipose-derived stem cell (adipoplus) for the treatment of crohn's fistula. in this study, patients are given injection of adipoplus in fistula site and followed for 8 weeks to evaluate the safety and efficacy.


Eligibility criteria:
inclusion criteria: * older than 18 years * prior diagnosis of crohn's disease * patients who have crohn's fistula * negative for serum beta-hcg for woman of childbearing age * agreement to participate, with signed informed-consent exclusion criteria: * patients who have allergy to bovine-derived materials or an anesthetic * patients with a diagnosis of auto immune disease except for crohn's disease * diagnosis of hbv, hcv, hiv and other infectious disease * patients who have a symptom of septicemia * patients with a diagnosis of active tuberculosis * patient who are pregnant or breast-feeding * patients who are unwilling to use an "effective" method of contraception during the study * patients with a diagnosis of inflammatory bowel disease except for crohn's disease * patients who are sensitive to fibrin glue * patients who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker * insufficient adipose tissue for manufacturing of adipoplus * patients who are considered not suitable for the study by investigator * patients with a diagnosis of active refractory crohn's disease * patients who have history of surgery for malignant cancer in the past 5 years * patients who have \> 2 cm diameter of fistula
effect of medical interventions in insulin resistance on prevalence of abnormal glucose tolerance

Conditions: Insulin Resistance

Summary: this research would take medical interventions in subjects of insulin resistance without abnormal glucose tolerance, to see if there were different prevalence of abnormal glucose tolerance in different groups.

the situation of type 2 dm prevention in china is serious. the commonly accepted natural course of type 2 dm is as follows: obesity, insulin resistance(hyperinsulemia), abnormal glucose tolerance, dm and complications of dm; correspondently, the function status of pancreas islet β cells are: normal, compensatory, decompensatory, impaired and failure. post researches have proved that using medical interventions after the period of insulin resistance when the function status of β cells were compensatory, the course could not be reversed. there were few clinical researches about effects of medical interventions in the period of insulin resistance . this research would take medical interventions in subjects of insulin resistance without abnormal glucose tolerance, to see if there were different prevalence of abnormal glucose tolerance in different groups.

Eligibility criteria:
inclusion criteria: * bmi \> 28kg/m2 * diagnosis of insulin resistance exclusion criteria: * abnormal glucose tolerance * function impairment of heart, liver or kidney

Keywords: insulin resistance abnormal glucose tolerance dm prevention
a comparison of two therapeutic strategies for the treatment of aspirin-associated peptic ulcers

Conditions: Peptic Ulcer

Summary: esomeprazole plus aspirin compared with esomeprazole alone for the treatment of aspirin-related peptic ulcers.

the aims of this study are to compare esomeprazole plus aspirin with esomeprazole alone in the treatment of aspirin-related ulcers. patients with aspirin-related peptic ulcers are randomized to receive esomeprazole (40 mg/day) plus aspirin (100 mg/day) or esomeprazole (40 mg/day) alone for 8 weeks. follow-up endoscopy was carried out at the end of the eighth week. the primary end point was the healing of peptic ulcers.

Eligibility criteria:
inclusion criteria: * aspirin users who have a peptic ulcer confirmed by endoscopy exclusion criteria: * serious medical illness (including cardiovascular events within 6 months before endoscopy) * acute gastrointestinal bleeding * a history of gastric or duodenal surgery * allergic to the study drugs * require long-term treatment with non-aspirin nonsteroidal anti-inflammatory drugs (nsaids), antiplatelet agents, or anticoagulant agents * pregnancy

Keywords: aspirin peptic ulcer
assessment of the humanisation of care in hospitals in andalusia-spain

Conditions: PROM; Satisfaction, Patient; Satisfaction, Personal; Stress; Burnout, Professional; Hospital Acquired Condition; Adverse Event; Nurse-Patient Relations

Summary: observational assessment through patient interviews of relational, structural and organisational aspects related to the humanisation of health care. these data will be related to health outcomes such as pain, sleep quality, anxiety levels, adverse events (pressure injuries, falls, and mortality), satisfaction with the care received, and experience in communication processes with health professionals. data will also be collected on work ergonomics variables (stress, burnout, working conditions, ratios) of nurses and health technicians, which will also be related to the health outcomes collected.


Eligibility criteria:
inclusion criteria: * all patients admitted to the internal medicine and emergency units of the participating hospitals during the sampling time. exclusion criteria: * patients presenting with haemodynamic instability or emergencies at the time of sampling * patients with cognitive impairment

Keywords: humanization of care health outcomes
a study to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary sjogren's syndrome.

Conditions: Primary Sjögren Syndrome

Summary: the purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary sjogren's syndrome.


Eligibility criteria:
inclusion criteria: * meet the 2016 american college of rheumatology (acr) / european league against rheumatism classification criteria for sjogren's syndrome (eular ss) * essdai score ≥6 * igg \>16 g/l * positive anti-ss-a/ro antibody at screening exclusion criteria: * pregnancy or breast feeding * secondary sjogren's syndrome * severe renal or haematological failure, a history of cancer, hepatitis b or c, human immunodeficiency virus, severe diabetes or any other chronic disease or evidence of infection * prior administration of any of the following: 1. rituximab in the past 12 months prior to randomization; 2. cyclophosphamide, mycophenolate mofetil, methotrexate, leflunomide and iguratimod in the past 12 weeks prior to randomization; 3. azathioprine, cyclosporin, tacrolimus, sirolimus, sulfasalazine in the past 4 weeks prior to randomization; 4. live vaccine in the past 12 weeks prior to randomization * corticosteroids: \> 10 mg/day oral prednisone (or equivalent); any change or initiation of new dose within 4 weeks prior to randomization; intramuscular, subcutaneous, intravenous, or intra-articular corticosteroids within 4 weeks prior to randomization.
mucormycosis clinical core for the mucor-advance p01 project

Conditions: Mucormycosis

Summary: to collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.

primary objective: to establish md anderson mucormycosis clinical core for the mucor-advance p01 project. * to prospectively identify, collect, and store all isolates causing proven or probable mcm in adult high-risk cancer participants. * to prospectively identify, collect, and store relevant host samples from high-risk participants developing proven or probable mcm, along with relevant biospecimens from three control groups. * to comprehensively annotate clinical specimens and provide information regarding the course and outcome of all mcm cases and controls. outline: this is an observational study. patients are assigned to 1 of 4 groups. group m: patients with mucormycosis undergo collection of blood, tissue and bal fluid samples as well as have their medical records reviewed on study. group a: patients with mucormycosis undergo collection of blood, tissue and bal fluid samples as well as have their medical records reviewed on study. group b: patients with mucormycosis undergo collection of blood, tissue and bal fluid samples as well as have their medical records reviewed on study. group c: patients with mucormycosis undergo collection of blood, tissue and bal fluid samples as well as have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection. * patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care. exclusion criteria: • patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.
peripheral venous catheter and masking tape

Conditions: Personal Satisfaction; Pain; Comfort

Summary: urpose: this study will be carried out to determine the effect of two different catheter covers on the comfort, satisfaction, pain level of the patient and the satisfaction of the nurse. materials and methods: this study, which is planned as an open-label randomized controlled post-test study, will be carried out between december 2021 and february 2022. data; descriptive properties will be collected with the information form and visual analog scale (visual analog scale-vas). data will be collected face to face by researchers.

peripheral venous catheter (pvk) is applied to patients who apply to the hospital due to outpatient chemotherapy and need to receive treatment by intravenous route. this application is carried out by nurses. during their education, nurses receive theoretical and practical training on pvc applications. nurses; they are the primary health professionals who are responsible for determining the pvc site, deciding on the catheter number to be used, applying the correct technique, performing the recommended intravenous (iv) interventions, following the complications that may develop by performing the necessary controls, ensuring the continuity of the application and providing catheter care. the effective application of interventions such as transfusion of intravenous fluids, chemotherapy drugs, blood and blood products, and total parenteral feeding in cancer patients is provided by pvk. the application of pvc is a necessity for the treatment of the individual receiving treatment and may cause pain, deterioration in comfort and dissatisfaction. although the widespread use of peripheral venous catheters provides great benefits, it has been reported that undesirable events such as phlebitis, infiltration, obstruction, leakage, and rarely infection occur when applied incorrectly and inadequately. in order for peripheral venous catheters to be used effectively in treatment, it is important to fix them with the correct technique. detection becomes more important in the use of chemotherapy agents. the patches used for fixation adhere to the glove and are difficult to remove from the patient's skin. therefore, both the nurse and the patient feel discomfort. for this reason, it would be appropriate to use a material that can be easily torn off with a glove, does not adhere to the glove, and fixes the patient's catheter well. this product should also be able to be easily removed without harming the patient's skin.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * being open to communication and cooperation * being conscious and able to answer questions * volunteering for research * being receiving chemotherapy treatment with a peripheral venous catheter exclusion criteria: * having a disease that may affect the ability to make decisions (dementia, psychological disorders, etc.) * having sensory losses such as vision and hearing * being in terminal period

Keywords: peripheral venous catheter chemotherapy patch fixation
impact of vitamin d supplementation on lactation associated bone loss

Conditions: Osteoporosis

Summary: studies have shown that lactation is associated with a loss of bone density from four to seven percent at the spine and hip among women who lactate for six months. decline in bone density with lactation occurs rapidly. although bone density increases after weaning, there is controversy on whether or not it is completely restored. epidemiological studies find no significant negative impact of lactation on bone mass or fractures, and in fact there is evidence that lactation has a positive effect on bone mass. we think that interventions that attenuate this physiologic loss of bone that is associated with lactation and accelerate restoration of bone mass after weaning may result in improved long term bone mass and diminished fracture risk.

adequate vitamin d stores are necessary for skeletal health. vitamin d deficiency is pronounced in women of child bearing age as well as pregnant women in the united states. this study will provide important information about whether vitamin d supplementation may positively impact the normal physiologic loss of bone mass that is observed during lactation. recruitment will begin while subjects are pregnant in order to expedite entry into the study in the immediate post-partum period. if subjects are deemed eligible during pregnancy, contact information to include name, address, expected delivery date and two contact phone numbers will be obtained. subjects will be contacted two weeks prior to expected delivery date and then again at expected delivery date. subjects will be followed for a total of 18 months.

Eligibility criteria:
inclusion criteria: * fully lactating mothers age 18 and up * within 1 month after delivery * plan to breast feed for at least 6 months exclusion criteria: * known metabolic bone disease * chronic renal insufficiency * chronic corticosteroid use * eating disorder * estrogen containing hormonal contraception use * daily use of \>400iu vitamin d supplementation * delivery of multiples * delivery of a singleton with a birth weight of \<2500 grams * preterm delivery of baby * history of kidney stones
craving and lifestyle management through mindfulness pilot study

Conditions: Obesity

Summary: the purpose of this study is to determine whether an innovative program that combines mindfulness-based stress reduction and mindful eating practices with diet and exercise guidelines (calmm+ intervention) will lead to greater weight loss and more favorable body fat distribution than a conventional weight-loss program(diet-ex intervention).

obesity is an important growing epidemic, with about 65% of americans overweight (flegal, carroll et al. 2002). psychological stress is widely cited anecdotally as a factor that causes people to engage in overeating, and studies provide strong evidence that stress can promote obesity. stress induces selective preference of sweet, high-fat food and increases visceral fat depots. chronic stress has also been shown to impair immune responses, including decreasing immune responses to vaccination. the proposed study will pilot test an innovative program that combines stress reduction and mindful eating practices with diet and exercise, craving and lifestyle management through mindfulness (calmm+). this program will be compared with diet and exercise intervention alone (diet-ex). approximately 20 persons will be randomized to the two groups, which will meet weekly for 16 weeks. key outcome measures are weight, fat distribution (as measured by waist/hip ratio), perceived stress, and mood. these measures will be assessed in visits performed at baseline, 3 months, and 6 months. data from this study are intended to provide pilot data for use in planning a larger randomized, controlled trial that will compare the effects of the calmm+ and diet-ex interventions on the metabolic and psychological processes assessed in this pilot study.

Eligibility criteria:
inclusion criteria: * healthy female * aged 18-50 * bmi range 25-45 * negative urine glucose test * must be able to provide informed consent exclusion criteria: * male * age less than 18 or menopausal * clinical diagnosis of eating disorder, diabetes, polycystic ovary syndrome, and coronary artery disease * history of anginal chest pain without adequate evaluation * substance abuse, mental health or medical condition that might interfere with study participation * use of medications containing corticosteroids * breastfeeding * non- english speaker * pregnant or planning to get pregnant in the next 6 months * previous mindfulness based stress reduction training * initiation of new class of psychiatric medications in past 2 months * currently on a weight loss diet

Keywords: obesity mindfulness based stress reduction diet and exercise mindful eating stress
a study of the response to ag-86893 in patients with pterygium hyperemia

Conditions: Pterygium

Summary: a pterygium is a wing-shaped, benign tissue growth which forms on the surface of the conjunctiva and grows towards the cornea. it can eventually lead to vision impairment. the precise cause of pterygium formation is unknown but new blood vessel growth and fibroblastic structures are characteristics of the disease. ag-86893 is an eye drop being developed to treat hyperemia (redness) and growth of the pterygium. hypothesis 1. ag-86893 dosed three times daily for 28 consecutive days has an acceptable safety profile as measured by the incidence and severity of adverse events (aes) compared with vehicle 2. at least 1 concentration of ag-86893 is effective, as measured by the mean change from baseline in conjunctival hyperemia (redness), compared with vehicle


Eligibility criteria:
inclusion criteria: * good health with no clinically significant findings based on the medical history, electrocardiogram, vital signs, blood chemistry, hematology, and urinalysis findings, as determined by the investigator * females of childbearing potential must have a negative pregnancy test at baseline and must be on established, adequate contraception and males must use condoms if their partner is of childbearing potential and their female partner should also use an additional effective means of contraception, or they must agree to abstain from sexual intercourse with a female partner for the duration of the study; contraception should be continued for 3 months after the last dose. * presence of pterygium with associated conjunctival hyperemia (redness) of grade ≥2 as assessed by a central reading center. exclusion criteria: * history or presence of any ocular diseases other than pterygium or its sequelae (after-effects), including neoplasia (uncontrolled overgrowth) * diagnosis of ocular hypertension or glaucoma requiring use of intraocular pressure-lowering medication * use of contact lenses during the study in the study eye * history or evidence of ocular surgeries in the study eye at any time * history of liver dysfunction or current abnormal liver enzymes * pregnancy, plans for pregnancy, or breastfeeding during the study

Keywords: hyperemia
radiofrequency ablation versus stereotactic radiotherapy in colorectal liver metastases

Conditions: Colorectal Carcinoma; Liver Metastases

Summary: this randomized clinical phase iii trial is testing the efficacy of radiofrequency ablation (rfa) and stereotactic body radiotherapy (sbrt) in the treatment of colorectal carcinoma liver metastases. primary end point is local progression free survival.

patients with 1-4 inoperable colorectal liver metastases, no more 4 cm in diameter are randomized to either rfa or sbrt. primary end point i local progression free survival. chemotherapy is allowed before and after study treatment.

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the colon or rectum * liver metastases * inoperable (technical or medical) * 1-4 metastases * maximum 40 mm in diameter * suitable for both therapies, rfa and sbrt exclusion criteria: * uncontrolled extrahepatic disease and uncontrolled primary cancer * liver cirrhosis

Keywords: colorectal carcinoma liver metastases stereotactic body radiation therapy radiofrequency ablation
drain after elective laparoscopic cholecystectomy

Conditions: Cholelithiasis

Summary: the trial aims to assess the value of drains in elective laparoscopic cholecystectomy.

after laparoscopic gallbladder removal patients are randomized to have a suction drain positioned in the subhepatic space or to have a sham drain in the subhepatic space. the primary outcome measure will be the presence of subhepatic fluid collection at ultrasonographic examination on the first postoperative day. secondary outcome measures will be postoperative abdominal and shoulder tip pain, use of analgesics, nausea, vomiting and morbidity

Eligibility criteria:
inclusion criteria: * elective laparoscopic cholecystectomy exclusion criteria: * acute cholecystitis, cholangitis, or pancreatitis * no contraindication for the laparoscopic * no other additional procedure

Keywords: laparoscopy cholecystectomy drainage